Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic effect of current treatments remains limited progress .Neural hypoperfusion and immune deregulation are the two key pathologies associated with Autism. Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy. In this study, the safety and efficacy of hUC-MSCs and hCB-MNCs transplantation will be evaluated in patients with Autism.

To investigate the safety and efficacy of human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in patients of Autism.

Inclusion Criteria:

• Children between the ages of 3 and 12 years.
• DSM-IV diagnosis of Autistic Disorder.
• Total score of CARS ≥ 30.
• Parents or legal guardian willing to sign the ICF.

Exclusion Criteria:

• Any history of hypersensitivity to serum products, or other known drug and food allergy.
• History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's.
• History of Epileptic seizure activity in the past 6 months.
• Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.
• The global autism ratings are assessed as being absent, minimal or mild.
• Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive dyskinesia.
• Subjects who have displayed significant self-injurious behavior (children who have caused visible harm to themselves).
• HIV+
• Acute and chronic hepatitis.
• Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.
• Severe pulmonary and hematological disease, malignancy or hypo-immunity.
• Currently undertaking other treatment that may affect the safety/efficacy of stem cells.
• Enrollment in other trials in the last 3 months.
• Other criteria the investigator consider improper for inclusion.